成纤维生长因子受体在非小细胞肺癌中的研究进展

Advanced Research of Fibroblast Growth Factor Receptor in Non-small Cell Lung Cancer

肺癌严重威胁人类的健康,近年来肺腺癌的治疗方式取得了巨大的进展,许多靶向治疗药物已广泛应用于临床并不同程度的使患者受益。而肺鳞癌中表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变以及ALK融合基因发生率低,使用吉非替尼及克唑替尼等酪氨酸激酶抑制剂治疗有效率低。一直以来成纤维生长因子(fibroblast growth factor,FGF)通路的异常被认为与肿瘤的增殖、血管生成等方面密切相关,近年越来越多的研究发现非小细胞肺癌中存在成纤维生长因子受体1(fibroblast growth factor receptor 1,FGFR1)基因扩增,体外及体内实验发现阻断FGF通路可降低肿瘤细胞的增殖、抑制远处转移、逆转靶向治疗耐药。本文就FGFR在非小细胞肺癌中的表达以及作为治疗靶点的前景作一综述。

Lung cancer is severely threatening human health. In recent years, the treatment for lung adenocarci-noma has made a great progress, targeted therapy has been widely applied in clinic, and beneifts amount of patients. However, in squamous cell lung cancer, the incidence of epidermal growth factor receptor （EGFR） gene mutant and ALK fusion gene are low,and targeted therapy like Tarceva and crizotinib, can hardly work. Since the ifbroblast growth factors （ifbroblast growth fac-tor, FGF） pathway is considered to be related to tumor cell proliferation, metastasis and angiogenesis, more and more research-es proved the ampliifcation of ifbroblast growth factor receptor （FGFR） in squamous cell lung cancer. Experiments in vivo and in vitro found that blocking FGF pathway could reduce the proliferation of tumor cells and inhibit metastasis. hTe FGF pathway might be a new target for treatment of squamous cell lung cancer. hTis article reviews the effect of FGFR in tumorigenesis,as well as the prospect as a therapeutic target in non-small cell lung cancer.